A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial
Conclusions. A single dose of ZOL administered at ART initiation prevented ART-induced bone loss through the first 48 weeks of ART, the period when ART-induced bone loss is most pronounced. Validation of these results in larger multicenter randomized clinical trials is warranted.
Clinical Trials Registration. NCT01228318.
Source: Clinical Infectious Diseases - Category: Infectious Diseases Authors: Ofotokun, I., Titanji, K., Lahiri, C. D., Vunnava, A., Foster, A., Sanford, S. E., Sheth, A. N., Lennox, J. L., Knezevic, A., Ward, L., Easley, K. A., Powers, P., Weitzmann, M. N. Tags: HIV/AIDS Source Type: research
More News: Clinical Trials | HIV AIDS | Infectious Diseases | Norvir | Orthopaedics | Reclast | Study | Truvada | Viread | Zometa